BioCentury | Aug 3, 2018
Clinical News

Sanofi drops two clinical assets; reports rebounding Dupixent sales

...breast cancer (TNBC); treat tuberculosis Endpoint: NA Status: Development discontinued Milestone: NA Jennie Walters HuDS6-DM4 (SAR566658) ImmunoGen Inc. Sanofi Carbonic anhydrase IV (CAIV...
BioCentury | Jun 1, 2009
Clinical News

Zeltia preclinical data

...ocular hypertension induced by oral gravage. Data on the topically administered siRNA directed against carbonic anhydrase IV (CAIV...
BioCentury | Jan 7, 2008
Finance

New products to watch

...Complicated intra-abdominal and complicated urinary tract infections U.S. MedImmune, a subsidiary of AstraZeneca (LSE:AZN; NYSE:AZN) CAIV-T...
BioCentury | Jul 16, 2007
Company News

Drug Royalty, University of Michigan deal

...million based on undisclosed conditions. In January, FDA approved a refrigerator-stable formulation of FluMist (formerly CAIV-T...
BioCentury | Jul 11, 2007
Company News

Drug Royalty acquires FluMist royalties

...million in sales last year. In January, FDA approved a refrigerator-stable formulation of FluMist (formerly CAIV-T...
BioCentury | May 21, 2007
Finance

Ebb & Flow

...CAIV-T intranasal influenza vaccine to include children 12-59 months of age without history of wheeze. CAIV-T...
BioCentury | May 21, 2007
Clinical News

CAIV-T vaccine regulatory update

...Vaccines and Related Biological Products Advisory Committee voted in favor of expanding the label of CAIV-T...
...proposed population, and 9-6 that the benefits exceed the risks. The committee voted 14-1 that CAIV-T...
...the risks in children 6-23 months regardless of wheezing history. The committee voted unanimously that CAIV-T...
BioCentury | May 17, 2007
Company News

FDA panel backs expanded label for CAIV-T

...Vaccines and Related Biological Products Advisory Committee voted in favor of expanding the label of CAIV-T...
...proposed population and 9-6 that the benefits exceed the risks. The committee voted 14-1 that CAIV-T...
...111 study in children 6-59 months of age that showed that 12 (0.3%) of the CAIV-T...
BioCentury | May 15, 2007
Company News

FDA releases CAIV-T documents

...the Vaccines and Related Biological Products Advisory Committee on Wednesday whether the benefit/risk profile of CAIV-T...
...MICP 111 study in children 6-59 months of age showed that 12 (0.3%) of the CAIV-T...
...respiratory adverse events identified in MICP 111" should be discussed, and that "risks associated with CAIV-T...
BioCentury | Apr 30, 2007
Strategy

Scale was elusive

...clamoring for the company to seek alternatives. The expected launches of two potential blockbusters - CAIV-T...
...that around this year, with the expected launch of CAIV-T for the 2007-08 flu season. CAIV-T...
...advantages compared with FluMist, including ease of distribution and the potential for a broader label. CAIV-T...
Items per page:
1 - 10 of 75